胃食管反流药物全球市场研究报告-2023-2030 年行业分析、规模、份额、增长、趋势和预测

全球对胃食管反流药物市场的需求将从 2022 年的 78 亿美元扩大到 2030 年的近 124.5 亿美元，预计 2023-2030 年研究期间的复合年增长率将达到 6.02%。

胃食管反流装置 (GERD) 提供了另一种治疗胃灼热的方法。 GERD 是下食管括约肌 (LES) 鬆弛或功能障碍，导致胃液回流到食道，引起胃灼热的一种病症。 压力、食管裂孔疝、腹部肥胖和吸烟都是 GERD 的危险因素。 这些装置的优势在于它们提供了一种微创手术选择来解决固有的解剖畸形。 此外，机器进行治疗的医疗支持的发展正在逐渐普及。 然而，最大的缺点是它仍然需要临床证明。

市场动态：

胃食管反流病患病率上升、生活方式改变和意识提高等主要因素预计将刺激胃食管反流病市场。 此外，随着支持性临床证据的增加，这些设备在微创手术中的应用正在稳步取得进展。 这在执行防止酸性和非酸性物质反流的手术时很有用，例如口腔笔记本电脑手术。 另一方面，由于用于治疗胃酸反流的常用药物已失去专利，市场可能会下滑。 然而，胃灼热在全球范围内呈上升趋势，因此未来胃食管反流药物市场可能会扩大。

这份研究报告解释了波特的五力模型、市场吸引力分析和价值链分析。 这些工具可帮助您清楚地了解您的行业结构并评估您在全球范围内的竞争吸引力。 此外，这些工具还提供了对全球胃食管反流药物市场各个部分的全面评估。 胃食管反流药物行业的发展和趋势为这项研究提供了一种整体方法。

市场细分：

本部分按国家和地区提供详细的细分数据，以帮助确定每种产品/服务的目标受众和未来商机。

按药物类型

• 抗酸剂
• H2 受体阻滞剂
• 质子泵抑製剂 (PPI)
• 促动力银色

按地区分析：

本部分涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲、中东和非洲胃食管反流药物市场当前和未来的需求。 此外，该报告重点关注所有主要地区每个单独应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的综合概况和全球竞争格局的详细视图。 胃食管反流药物市场的主要参与者是 AstraZeneca PLC、Eisai Co., Ltd.、GlaxoSmithKline PLC、Takeda Pharmaceutical Co. Ltd.、Takeda Pharmaceutical Company Limited、Johnson & Johnson K.K. 本节概述了竞争格局，包括各种战略发展，例如主要併购、未来能力、合作伙伴关係、财务概览、联合研究、新产品开发和新产品发布。

内容

第一章前言

• 报告内容
  • 目的
  • 目标受众
  • USP（独特的销售建议）及其提供的内容
• 调查范围
• 调查方法
  • 市场调研流程
  • 市场研究方法

第 2 章执行摘要

• 市场亮点
• 全球市场概况

第3章胃食管反流药-行业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场製约因素
• 机会
• 行业趋势
• 波特的五力分析
• 市场吸引力分析
  • 按药物类型进行的市场吸引力分析
  • 市场吸引力分析：按地区

第四章价值链分析

• 价值链分析
• 原材料分析
  • 原材料清单
  • 原材料製造商名单
  • 主要原材料价格走势
• 潜在买家名单
• 营销渠道
  • 直接营销
  • 间接营销
  • 市场发展趋势

第 5 章 COVID-19 爆发的影响分析

第6章胃食管反流药物全球市场分析：按药物类型分列

• 药物类型概述
• 过去和未来的数据
• 按药物类型分析
• 抗酸剂
• H2 受体阻滞剂
• 质子泵抑製剂 (PPI)
• 促动力银色

第7章全球胃食管反流药物市场分析：分地区

• 区域展望
• 简介
• 北美销售分析
  • 概览、历史和预测销售分析
  • 北美各部门的销售分析
  • 北美销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史和预测销售分析
  • 按细分市场进行的欧洲销售分析
  • 按国家/地区划分的欧洲销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 意大利销售分析
  • 俄罗斯销售分析
  • 其他欧洲销售分析
• 亚太地区销售分析
  • 概览、历史和预测销售分析
  • 亚太地区各部门的销售分析
  • 亚太国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本的销售分析
  • 韩国销售分析
  • 澳大利亚销售分析
  • 其他亚太地区销售分析
• 拉丁美洲销售分析
  • 概览、历史和预测销售分析
  • 拉丁美洲各部门的销售分析
  • 拉丁美洲国家/地区的销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利的销售分析
  • 其他拉丁美洲销售分析
• 中东和非洲销售分析
  • 概览、历史和预测销售分析
  • 中东和非洲各细分市场的销售额分析
  • 中东和非洲国家/地区的销售分析
  • 沙特阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 其他中东和非洲销售分析

第八章胃食管反流药企业竞争格局

• 胃食管反流药物市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他扩展

第九章公司简介

• 顶级公司的市场份额分析
• 市场集中度
• 阿斯利康公司
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• 卫材有限公司
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• 葛兰素史克公司
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• 武田製药有限公司
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• 强生公司。
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势

注意：公司简介中的财务信息和近期发展基于可用信息，可能不包括私营公司。

The global demand for Gastroesophageal Reflux Disease Therapeutics Market is presumed to reach the market size of nearly USD 12.45 BN by 2030 from USD 7.8 BN in 2022 with a CAGR of 6.02% under the study period 2023 - 2030.

Gastroesophageal reflux disease therapeutics device (GERD) provides an alternate method for treating heartburn. It is essentially a condition wherein the lower esophageal sphincter (LES) relaxes or fails to function effectively, allowing stomach liquids to reflux back into the oesophagus, thus, causing heartburn. Stress, hiatal hernia, abdominal obesity, and smoking are all risk factors for GERD. These devices are advantageous as they provide an option for minimally invasive surgery to address inherent anatomical deformities. They are slowly gaining ground with evolving supportive medical proofs for machines to carry out the treatment. However, their biggest disadvantage is that they still need to be clinically proven.

Market Dynamics:

Major factors such as the rising prevalence of gastrointestinal reflux diseases, changing lifestyles, and increasing awareness are expected to fuel the gastroesophageal reflux disease therapeutics market. Further, using these devices for minimally invasive procedures is steadily gaining traction with growing supportive clinical evidence. This will help perform procedures, such as transoral fundoplication, which prevent acid and non-acid contents' reflux. On the downside, the market may experience a decline due to the patent expiration of popular medications used to treat acid reflux diseases. Nonetheless, the gastroesophageal reflux disease therapeutics market is set to expand in the future years as heartburn prevalence increases globally.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of gastroesophageal reflux disease therapeutics. The growth and trends of gastroesophageal reflux disease therapeutics industry provide a holistic approach to this study.

Market Segmentation:

This section of the gastroesophageal reflux disease therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

• Antacids
• H2 Receptor Blockers
• Proton Pump Inhibitors (PPIs)
• Pro-Kinetic Agents

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Gastroesophageal Reflux Disease Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the gastroesophageal reflux disease therapeutics market include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Co. Ltd., and Johnson & Johnson. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Type
  • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET ANALYSIS BY DRUG TYPE

• 6.1 Overview by Drug Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Drug Type
• 6.4 Antacids Historic and Forecast Sales by Regions
• 6.5 H2 Receptor Blockers Historic and Forecast Sales by Regions
• 6.6 Proton Pump Inhibitors (PPIs) Historic and Forecast Sales by Regions
• 6.7 Pro-kinetic Agents Historic and Forecast Sales by Regions

7 . GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS COMPANIES

• 8.1. Gastroesophageal Reflux Disease Therapeutics Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. AstraZeneca PLC
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Eisai Co. Ltd.
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. GlaxoSmithKline PLC
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. Takeda Pharmaceutical Co. Ltd.
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Johnson & Johnson.
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Drug Type (USD MN)
• Antacids Market Sales by Geography (USD MN)
• H2 Receptor Blockers Market Sales by Geography (USD MN)
• Proton Pump Inhibitors (PPIs) Market Sales by Geography (USD MN)
• Pro-kinetic Agents Market Sales by Geography (USD MN)
• Global Gastroesophageal Reflux Disease Therapeutics Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Gastroesophageal Reflux Disease Therapeutics Report
• Market Research Process
• Market Research Methodology
• Global Gastroesophageal Reflux Disease Therapeutics Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Drug Type
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Drug Type (USD MN)
• Antacids Market Sales by Geography (USD MN)
• H2 Receptor Blockers Market Sales by Geography (USD MN)
• Proton Pump Inhibitors (PPIs) Market Sales by Geography (USD MN)
• Pro-kinetic Agents Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.